As discussed above, ODZ4 was found to be altered, in terms of gene rearrangements, mutations, and overexpression, in all of the breast cancer subtypes analyzed, with there being a clinical correlation with worse patient RFS and OS in at least TNBC-, HER2-, and PR-positive patients. Here, ERBB2 is linked to breast cancer.